6 research outputs found
Recommended from our members
Early intervention in a mouse model of childhood obesity: effects on brown adipose tissue function
Due to the high childhood obesity rates within the United States, it is necessary to develop efficacious strategies to combat childhood obesity. To explore whether early intervention can produce lasting metabolic improvements, we used a mouse model of genetically-induced hypothalamic leptin resistance (LeprNkx2.1knockout, hereby known as KO) that exhibits early-onset hyperphagia and obesity. We found that KO mice exhibit reduced capacity of the brown adipose tissue (as seen by disorganized mitochondrial structure). Brown adipose tissue capacity can be restored by paired-feeding in the peri-weaning period, leading to persistent improvements in later adiposity even after restriction ends. These studies lead us to investigate the maturation process of brown adipose tissue in the peri-weaning period. We found that brown adipose tissue expansion between 2 to 3 weeks of age is accompanied by a reduced thermogenic capacity in control mice, as determined by protein levels of uncoupling protein 1 and disorganization of the mitochondrial cristae. Thermogenic function was restored by 5 weeks of age, as demonstrated by a peak of uncoupling protein 1, in control mice but not KO mice. Paired-feeding of KO mice in the peri-weaning period rescued this peak at 5 weeks of age. These studies elucidate a critical period when brown adipose tissue expansion is followed by activation. The magnitude of brown adipose tissue activation at this time might be predictive of future obesity and metabolic rate, highlighting a potential therapeutic time window in which to intervene in pediatric obesity
Oligomalt, a New Slowly Digestible Carbohydrate, Is Well Tolerated in Healthy Young Men and Women at Intakes Up to 180 Gram per Day: A Randomized, Double-Blind, Crossover Trial
In this randomized, double-blind triple-crossover study (NCT05142137), the digestive tolerance and safety of a novel, slowly digestible carbohydrate (SDC), oligomalt, an α-1,3/α-1,6-glucan α-glucose-based polymer, was assessed in healthy adults over three separate 7-day periods, comparing a high dose of oligomalt (180 g/day) or a moderate dose of oligomalt (80 g/day in combination with 100 g maltodextrin/day) with maltodextrin (180 g/day), provided as four daily servings in 300 mL of water with a meal. Each period was followed by a one-week washout. A total of 24 subjects (15 females, age 34 years, BMI 22.2 kg/m2, fasting blood glucose 4.9 mmol/L) were recruited, of whom 22 completed the course. The effects on the primary endpoint (the Gastrointestinal Symptom Rating Score (GSRS)) showed a statistically significant dose dependency, albeit of limited clinical relevance, between a high dose of oligomalt and maltodextrin (mean (95% CI) 2.29 [2.04, 2.54] vs. 1.59 [1.34, 1.83], respectively; difference: [â1.01, â0.4], p < 0.0001), driven by the GSRS-subdomains âIndigestionâ and âAbdominal painâ. The GSRS difference ameliorated with product exposure, and the GSRS in those who received high-dose oligomalt as their third intervention period was similar to pre-intervention (mean ± standard deviation: 1.6 ± 0.4 and 1.4 ± 0.3, respectively). Oligomalt did not have a clinically meaningful impact on the Bristol Stool Scale, and it did not cause serious adverse events. These results support the use of oligomalt across various doses as an SDC in healthy, normal weight, young adults